DLBCL: Clinical Trials

2 trials for DLBCL, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 unknown. 2 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Unknown 2
Phase 21Unknown 1

Follow DLBCL: new trials by email Literature Review of DLBCL trials Research Report on DLBCL

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression
Selinexor combined with Prednisone, Etoposide, and Lenalidomide - DLBCL
Phase 1 / Phase 2UnknownThe Affiliated Hospital of Qingdao University672022-10-012022-08-19
Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)
IBI110 plus sintilimab, IBI110 - DLBCL
Phase 1UnknownInnovent Biologics (Suzhou) Co. Ltd.502021-09-272021-09-09

Narrower conditions

Recurrence (1)

Broader conditions

Disease Attributes (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

Etoposide (1)  ·  Lenalidomide (1)  ·  Prednisone (1)  ·  sintilimab (1)

Sponsors

Innovent Biologics (Suzhou) Co. Ltd. (1)  ·  The Affiliated Hospital of Qingdao University (1)

Countries

China (2)